Study: Intensive ranibizumab treatment boosts DME outcomes

10/15/2012 | Medscape (free registration)

Intensive therapy with ranibizumab, a monoclonal antibody that inhibits vascular endothelial growth factor, fared better than laser therapy alone or laser therapy plus ranibizumab in improving best-corrected visual acuity and foveal thickness in diabetic macular edema patients between 24 and 36 months, a study indicated. The findings in the Archives of Ophthalmology demonstrate that using anti-VEGF agents is safe and effective for treating DME, researchers noted.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care